Johnson & Johnson Press Releases

June 1, 2025

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target

May 28, 2025

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 28, 2025

Johnson & Johnson MedTech Announces New Clinical Data for the MONARCHTM Platform for Robotically-Assisted Bronchoscopy

Largest multi-center prospective robotically-assisted bronchoscopy (RAB) study to date contributes to cannon of scientific evidence and advances clinical understanding

May 22, 2025

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA

New CARVYKTI® data help shift the treatment paradigm in relapsed or refractory multiple myeloma with five-year progression-free survival rates Late-breaking AKEEGA® data selected for ASCO Press Program, showcasing prostate cancer leadership and potential in patients with HRR-altered mCSPC Early results from next-generation molecules for leukemia, lymphoma, multiple myeloma and prostate cancer showcase pipeline strength

May 21, 2025

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

May 21, 2025

Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imagingi

New ultrasound catheter delivers superior image quality,i,ii peak maneuverability and seamless CARTO™ 3 System integrationi, giving physicians improved visualizationii for added confidence during cardiac ablation procedures

May 20, 2025

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma

May 20, 2025

Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025

EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools

May 15, 2025

Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025

23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio

May 14, 2025

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Press releases

Press Releases

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson MedTech Announces New Clinical Data for the MONARCHTM Platform for Robotically-Assisted Bronchoscopy

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference

Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imagingi

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025

Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

You are now leaving jnj.com

You are now leaving jnj.com

Search Results

No Results

Recently Viewed

Press releases

Press Releases

You are now leaving jnj.com

You are now leaving jnj.com